Yes, She Needs Tdap Again During This Pregnancy
Pregnant women should receive Tdap during each pregnancy, regardless of when they last received the vaccine—even if it was just in 2018. This recommendation applies irrespective of prior Tdap vaccination history 1, 2, 1.
The Core Recommendation
The Advisory Committee on Immunization Practices (ACIP) explicitly states that pregnant women are recommended to receive a dose of Tdap during each pregnancy to prevent pertussis in infants too young for routine vaccination 1. This is one of only two exceptions to the general rule against routine repeat Tdap dosing 1.
Optimal Timing
Administer Tdap between 27 and 36 weeks of gestation, preferably during the earlier part of this period 2, 1. The rationale is straightforward:
- Active transport of maternal antibodies doesn't substantially occur before 30 weeks gestation 3
- A minimum of 2 weeks is required to mount maximal immune response 3
- Earlier vaccination within the 27-36 week window maximizes maternal antibody response and passive transfer to the infant 2, 3
- Maternal antibodies wane quickly—even women immunized in first or second trimester have low antibody levels at term 3
However, Tdap may be administered at any time during pregnancy if there are special circumstances 2, 1.
Why Every Pregnancy?
The evidence supporting repeat vaccination in each pregnancy is compelling:
Infant Protection: Maternal Tdap vaccination is over 90% effective against pertussis in infants younger than 2 months of age 4. Multiple studies demonstrate that maternal immunization results in:
- Increased pertussis antibody concentrations in infants 4
- Reduction in infant disease severity and hospitalization 4
- No deaths observed among infants whose mothers received Tdap prior to 36 weeks 4
Antibody Waning: Anti-pertussis antibodies decline rapidly after the first year, and vaccine effectiveness begins to wane within 2-4 years after a single Tdap dose 1. Since your patient received Tdap in 2018, her antibody levels are likely insufficient to provide optimal passive immunity to her newborn.
Safety Considerations
The safety profile is reassuring:
- No major maternal or infant safety issues have been reported in the reviewed literature 4
- No evidence of adverse fetal effects from vaccinating pregnant women with inactivated vaccines or toxoids 2, 5, 6
- A large cohort study of 16,606 Tdap recipients showed no increased risks of small for gestational age or preterm delivery 7
- No evidence of appreciable risks for specific major malformations with early or late pregnancy exposure 8
Regarding repeat dosing: ACIP evaluated safety of administering Tdap at intervals <5 years after Td and recommended that Tdap should not be delayed and should be administered regardless of interval since last tetanus or diphtheria toxoid-containing vaccine 1. Recent data on successive pregnancies shows this remains safe, though transfer ratios may be slightly reduced with closely spaced pregnancies 9.
Common Pitfalls to Avoid
Don't skip vaccination because she received Tdap in 2018. The "with each pregnancy" recommendation is absolute and does not depend on interval since last dose.
Don't wait until postpartum. While postpartum Tdap is recommended if not given during pregnancy 2, prenatal vaccination is superior because it provides passive immunity to the infant during the most vulnerable first 2 months of life.
Don't confuse this with the general adult recommendation. For non-pregnant adults, a single lifetime Tdap dose is typically sufficient (with Td boosters every 10 years). Pregnancy is the specific exception requiring repeat dosing 1.
The recommendation is clear and evidence-based: administer Tdap during this pregnancy between 27-36 weeks gestation to protect her newborn from pertussis 2, 1.